K143482 is an FDA 510(k) clearance for the xevonta dialyzer. Classified as Dialyzer, High Permeability With Or Without Sealed Dialysate System (product code KDI), Class II - Special Controls.
Submitted by B. Braun Avitum AG (Melsungen, DE). The FDA issued a Cleared decision on March 1, 2016 after a review of 449 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.5860 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Gastroenterology & Urology submissions.
View all B. Braun Avitum AG devices
NCT01111266
Completed
Interventional
Industry-sponsored
Determination of in Vivo Ultrafiltration Coefficient (KUF) in Patients With Chronic Kidney Disease (CKD)
Evaluation of Performance and Safety Profile of Xevonta High Flux Dialyzer With Special Focus on Determination of in Vivo Ultrafiltration Coefficient in Patients With CKD
| Condition studied |
Kidney Disease |
| Study design |
Single group |
| Eligibility |
All sexes
· 18 Years+
|
| Principal investigator |
Jürgen Wagner, Prof. Dr. |
| Sponsor |
B.Braun Avitum AG
(industry)
|
Started 2010-03-01
→
Primary completion 2011-08-01
→
Completed 2012-03-01
Primary outcome
in vivo KUF
Secondary outcome
Determination of removal rates
Study completed - no results published.
This trial concluded in 2012 but has not posted
results to ClinicalTrials.gov. Completed studies without public results are common
in industry-sponsored device trials; the data may be referenced in the
510(k) Summary PDF or remain unpublished.
View full study on ClinicalTrials.gov